Search Within

Jae Hong Park

Formats
  1. Meeting Abstract (204)
  2. Journal Article (120)
  3. Review (18)
  4. Research Letter (6)
  5. Guidelines (3)
  6. Book Section (2)
  7. Correspondence (2)
  8. Editorial (1)
Groups
  1. Adult Leukemia (356)
  2. Center for Hematologic Malignancies (356)
  3. Department of Medicine (356)
  4. Hematologic Malignancies, Division of (356)
  5. GSK Faculty (182)
  6. Hematologic Malignancies Research (140)

More Groups

People
  1. Renier Brentjens (105)
  2. Isabelle Riviere (83)
  3. Michel Sadelain (81)
  4. Martin Tallman (79)
  5. Maria Palomba (71)
  6. Xiuyan Wang (65)

More People

Years
  1. 2025 (19)
  2. 2024 (23)
  3. 2023 (38)
  4. 2022 (34)
  5. 2021 (29)
  6. 2020 (24)

More Years

Publications
  1. Blood (132)
  2. Journal of Clinical Oncology (30)
  3. Blood Advances (14)
  4. Haematologica (9)
  5. Leukemia and Lymphoma (9)
  6. Transplantation and Cellular Therapy (9)

More Publications

Publishers
  1. American Society of Hematology (146)
  2. Elsevier Inc. (34)
  3. American Society of Clinical Oncology (32)
  4. Nature Publishing Group (29)
  5. Taylor & Francis Group (12)
  6. American Association for Cancer Research (10)

More Publishers

Results (356)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab
    Journal Article

    Wudhikarn, K.; King, A. C.; Geyer, M. B.; Roshal, M.; Bernal, Y.; Gyurkocza, B.; Perales, M. A.; Park, J. H.
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Impact of bridging chemotherapy on clinical outcomes of CD19-specific CAR T cell therapy in children/young adults with relapsed/refractory B cell acute lymphoblastic leukemia
    Journal Article

    Shahid, S.; Ramaswamy, K.; Flynn, J.; Mauguen, A.; Perica, K.; Park, J. H.; Forlenza, C. J.; Shukla, N. N.; Steinherz, P. G.; Margossian, S. P.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: A preclinical model and initial clinical experience
    Journal Article

    Palomba, M. L.; Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Rivière, I.; Sadelain, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos) – Associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients
    Research Letter

    Stoll, J. R.; Battle, L.; Moy, A.; Dusza, S. W.; Park, J. H.; Tallman, M. S.; Taylor, J.; Markova, A.
    Journal of the American Academy of Dermatology (2022)

    Fulltext@MSK | Save
  • Safety and pharmacokinetics of calaspargase pegol in adults with newly diagnosed Philadelphia-negative ALL: A phase 2/3 study
    Meeting Abstract

    Stock, W.; Park, J. H.; Emadi, A.; Abdul-Hay, M.; Cassaday, R. D.; Pullarkat, V. A.; Webster, J.; Pandya, S. S.; Mogul, M. J.; Shvenke, Y.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach
    Meeting Abstract

    Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of allogeneic hematopoietic cell transplantation (HCT) as consolidation following CD19 chimeric antigen receptor (CAR) T cell therapy for treatment of relapsed acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Park, J. H.; Nikiforow, S.; Kim, S.; Hu, Z. H.; Moskop, A.; Ahmed, S.; Abid, M. B.; Badar, T.; Bredeson, C.; Brown, V.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
    Blood (2021)

    Fulltext@MSK | Save